Table S4.

Univariate and multivariate analyses to identify clinical characteristics associated with the detection of CSF-tDNA

Characteristic assessed in univariate or multivariate analysisOdds ratio (95% confidence interval)P value
Univariate logistic regression
 Sex, female vs. male1.07 (0.23–4.92)0.93
 Recurrent, yes vs. no1.91 (0.19–18.93)0.58
 Race
  A vs. W0.15 (0.01–1.92)0.15
  AA vs. W1.79 (0.05–62.48)0.75
  ME vs. W0.15 (0.01–1.92)0.15
  AA vs. A11.67 (0.19–736)0.25
  ME vs. A1.00 (0.04–27.27)1
  ME vs. AA0.09 (0.001–5.40)0.25
 Hydrocephalus, yes vs. no2.40 (0.25–23.24)0.45
 Tumor grade, III and IV vs I and II20.57 (2.16–196)0.01
 Enhancing imaging, yes vs. no6.57 (0.52–83.75)0.15
 Tumor location
  Spinal vs. infratentorial0.66 (0.13–3.27)0.61
  Supratentorial vs. infratentorial7.29 (0.29–185)0.23
  Supratentorial vs. spinal11.0 (0.44–276)0.14
 Abutting CSF space, yes vs. no59.9 (2.14–1,669)0.02
 Sequencing method, panel vs. WES19.0 (0.90–401)0.06
 Location, promoter vs. exon and splice site6.03 (0.25–148)0.27
 Age1.01 (0.98–1.04)0.64
 Symptom duration0.98 (0.91–1.06)0.63
 Tumor size1.01 (0.99–1.02)0.41
 CSF volume0.98 (0.72–1.32)0.88
 Quantity of DNA in CSF1.00 (1.00–1.01)0.2
 Mutant allele fraction in tumor3.55 (0.04–298)0.58
Multivariate logistic regression
 Tumor grade, III and IV vs I and II26.51 (1.45–485)0.03
 CSF space, yes vs. no90.59 (1.07–7,670)0.05
  • A, Asian; AA, African American; ME, Middle Eastern; panel, directed sequencing of codons 130–139 of IDH1; codons 126–155, 144–178, and 250–262 of IDH2; all coding exons of TP53; and the TERT promoter (Materials and Methods); W, white.